Uppsala, Sweden, May 8, 2019: Biovica will participate in the 55th Annual Meeting of the American Society of Clinical Oncology (ASCO), taking place in Chicago May 31-June 4, 2019
ASCO brings together more than 32,000 oncology professionals from across the globe to share the latest clinical cancer research impacting patient care.
The Biovica team will attend the ASCO (American Society of Clinical Oncology) Annual Meeting in Chicago May 31-June 4. Take the opportunity to learn more about DiviTum®, our blood-based biomarker for evaluating modern cancer therapies and how it can support your oncology development projects.
Contact firstname.lastname@example.org to book a meeting on site.
Anders Rylander, CEO Biovica.
Phone: +46 (0)18 444 48 35,
Biovica develops and commercializes blood-based biomarker assays that improve monitoring of modern cancer therapies and predict patient outcome. The company’s DiviTum® assay, a test for accurately measuring cell proliferation, has successfully demonstrated its capabilities to early evaluate therapy effectiveness in several clinical trials. Biovica aims to make best-possible-treatment from day one a reality.
Biovica collaborates with world-leading cancer institutes as well as pharmaceutical companies launching next-generation therapies. The company is ISO 13485 certified for Quality Management Systems. DiviTum® is CE-labeled and MPA-registered. Appointed Certified Adviser to the company is FNCA Sweden AB, email@example.com, +46 8 528 00 399.
Read more: www.biovica.com